A Pituitary Society update to acromegaly management guidelines
Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Pituitary - 24(2021), 1 vom: 20. Feb., Seite 1-13 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Fleseriu, Maria [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 01.11.2021 Date Revised 01.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s11102-020-01091-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316486043 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316486043 | ||
003 | DE-627 | ||
005 | 20231225161202.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11102-020-01091-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1054.xml |
035 | |a (DE-627)NLM316486043 | ||
035 | |a (NLM)33079318 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Fleseriu, Maria |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Pituitary Society update to acromegaly management guidelines |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.11.2021 | ||
500 | |a Date Revised 01.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Acromegaly | |
650 | 4 | |a Growth hormone | |
650 | 4 | |a Insulin-like growth factor I | |
650 | 4 | |a Oral octreotide | |
650 | 4 | |a Pegvisomant | |
650 | 4 | |a Pituitary adenoma | |
650 | 4 | |a Somatostatin receptor ligand | |
650 | 7 | |a Receptors, Somatostatin |2 NLM | |
650 | 7 | |a Human Growth Hormone |2 NLM | |
650 | 7 | |a 12629-01-5 |2 NLM | |
650 | 7 | |a Insulin-Like Growth Factor I |2 NLM | |
650 | 7 | |a 67763-96-6 |2 NLM | |
650 | 7 | |a pegvisomant |2 NLM | |
650 | 7 | |a N824AOU5XV |2 NLM | |
650 | 7 | |a Octreotide |2 NLM | |
650 | 7 | |a RWM8CCW8GP |2 NLM | |
700 | 1 | |a Biller, Beverly M K |e verfasserin |4 aut | |
700 | 1 | |a Freda, Pamela U |e verfasserin |4 aut | |
700 | 1 | |a Gadelha, Monica R |e verfasserin |4 aut | |
700 | 1 | |a Giustina, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Katznelson, Laurence |e verfasserin |4 aut | |
700 | 1 | |a Molitch, Mark E |e verfasserin |4 aut | |
700 | 1 | |a Samson, Susan L |e verfasserin |4 aut | |
700 | 1 | |a Strasburger, Christian J |e verfasserin |4 aut | |
700 | 1 | |a van der Lely, A J |e verfasserin |4 aut | |
700 | 1 | |a Melmed, Shlomo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pituitary |d 1998 |g 24(2021), 1 vom: 20. Feb., Seite 1-13 |w (DE-627)NLM097524530 |x 1573-7403 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2021 |g number:1 |g day:20 |g month:02 |g pages:1-13 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11102-020-01091-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2021 |e 1 |b 20 |c 02 |h 1-13 |